NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Oncocyte Corporation's Chief Executive Officer, Josh Riggs, as the company works to disrupt the mature diagnostics marketplace with a nimble, capital-light approach to growth. Oncocyte (NASDAQ:OCX) has developed and is preparing to commercialize precision tests in the transplant and oncology markets. The Company's transplant diagnostic tests, VitaGraft™ and GraftAssure™, measure the health of a ...